Progesterone Troche: Mechanism of Action and Duration
Mechanism of Action
Progesterone troches work through both genomic and non-genomic pathways to exert their physiological effects, with absorption occurring directly through the buccal mucosa into systemic circulation.
Genomic Mechanisms
Progesterone acts primarily through nuclear progesterone receptors (PR-A and PR-B) that function as transcription factors 1. The key genomic mechanisms include:
- Nuclear receptor binding: Progesterone binds to specific progesterone receptors in target tissues, which then bind to cis-acting sequences in gene promoter regions to regulate transcription 2
- Decreased PR-A/PR-B ratio: This maintains uterine quiescence by altering gene expression patterns 1
- Steroid Receptor Coactivator (SRC) family interaction: These cofactors modulate the transcriptional activity of hormone receptors 2
- Anti-inflammatory effects: Decreases prostaglandin synthesis and infection-mediated cytokine production by fetal membranes and placenta 1
- Cervical effects: Reduces cervical stromal degradation and alters the barrier to ascending inflammation/infection 1
Non-Genomic Mechanisms
Progesterone also exerts rapid effects through membrane-bound receptors that do not require gene transcription 1:
- Membrane-bound progesterone receptors: Including PGRMC1 and PGRMC2, which integrate signals from progesterone, heme, and cytochrome P450 enzymes 3
- Vascular effects: Rapid vasodilation through nitric oxide synthase (NOS) and cyclooxygenase (COX) activation, with cross-talk between NO and prostacyclin pathways 4, 5
- Calcium modulation: Decreases vascular muscle cell calcium responses within minutes 5
Duration of Action
Peak plasma concentrations of progesterone from transbuccal troches occur within hours, with effects lasting approximately 12 hours, necessitating twice-daily dosing.
Pharmacokinetic Profile
Based on transbuccal administration studies 6:
- Absorption: Progesterone is readily absorbed via the buccal mucous membrane 6
- Peak concentrations: Achieved within the first few hours after administration, reaching levels comparable to those in young menstruating women 6
- Dosing interval: Plasma concentration-time profiles demonstrate coverage over a 12-hour period 6
- Recommended frequency: Twice-daily administration (every 12 hours) is required to maintain therapeutic levels 6
Clinical Dosing Context
While the evidence primarily addresses vaginal and intramuscular progesterone formulations for preterm birth prevention, oral progesterone studies provide relevant pharmacokinetic insights 1:
- Oral progesterone: Studies used 400 mg doses every 6-8 hours, suggesting relatively short duration of action requiring frequent dosing 1
- Sustained effect: For endometrial protection, oral progesterone capsules at 200 mg daily (cyclical) maintained adequate tissue effects over 28-day cycles 7
Important Caveats
The transbuccal route offers advantages over oral administration by bypassing first-pass hepatic metabolism, potentially providing more consistent bioavailability 6. However, individual variation in hormone metabolism and absorption can affect both peak levels and duration of action 8. The twice-daily dosing requirement reflects the relatively short half-life of natural progesterone compared to synthetic progestins.